Commentary: Outcome measures were flawed. Ebers GC BMJ. 2010; 340:c2693. PMID: 20522659. Abstract Comment1 commentRecommendBookmarkWatch Comments This is a great article by Dr Ebers, that outlines what MS neurologists see in their offices on a daily basis. Patients with EDSS scores of 3.0 and 4.5 or 5.0, for example, are hardly included in phase 3 clinical trials and even if they are, their outcomes are not elucidated (1) in the results and discussion section of the published data for each drug. I think it is not just a matter of flawed analysis, the data are probably left out or cherry-picked. The consequence is that when patients begin to worsen and disability begins to accumulate, particularly in the African-American (AA) population with MS, the odds are more than likely that the slide will continue; add to this the low percentage of AAs enrolled in phase 3 clinical trials and we have literally zero answers to their questions if the drugs they are on are working. Jagannadha Avasarala, MD, PhDGreenville Health System, SC Reference Avasarala JR. J of Clini Pharmacol 2015; 55(11): 1218-1220.